Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy

Figure 3

Cytotoxic activity by combination therapy of IL-4Rα-lytic hybrid peptide with gemcitabine. SK-1 was incubated with various concentrations of IL-4Rα-lytic hybrid peptide (0–20 μM) and gemcitabine (0–30 nM). The results are represented as mean ± SD (bars) of triplicate determinations, and the assay was repeated three times.